NCBiotech News

We work hard to bring you news about North Carolina’s wide-ranging life sciences community. Please feel free to share it with others. And let us know if you have something we should know about.

Early- to late-stage life science companies have until July 31 to submit applications to present at the 2018 Southeast BIO Investor & Partnering Forum to be held in Atlanta November 13-14.
Cereius, Inc., a young Durham biotechnology company developing new methods to cross the well-fortified blood-brain barrier to treat cancer that has spread to the brain, has received critical reinforcements in that battle: An NCBiotech loan and $6.5 million in a Series A equity round.
Durham-based hearing technology company MED-EL USA has been granted a U.S. Food and Drug Administration clearance to market its BONEBRIDGE bone conduction hearing implant system in the United States.
Durham-based Aerie Pharmaceuticals, an ophthalmic pharmaceutical company, has reported positive developments on its regulatory and financial fronts.
Three North Carolina companies joined the prestigious list of participants in the 2018 MedTech Innovator Accelerator and Showcase programs. The Los Angeles-based non-profit is a global competition and accelerator for medical device, digital health and diagnostic companies.
Research Triangle Park-based AgBiome, which harnesses plant microbiomes to develop novel crop protection products, has secured $65 million in Series C financing.

Raleigh bioscience startup Locus Biosciences, a spinout of North Carolina State University, is using a version of the hot gene-editing technology called CRISPR to cut a new path to the discovery and development of novel antibiotics.

Locus Biosciences, a fast-emerging RTP company using genetic tricks to whack drug-resistant bacteria, has acquired EpiBiome, a young California firm with a high-speed technology platform that will add even more focus to Locus.
Shareholders of Durham-based BioCryst Pharmaceuticals have rejected a January 2018 merger agreement with Pennsylvania-based Idera Pharmaceuticals, in a special vote that will keep BioCryst in the Triangle.
KeraNetics of Winston-Salem has reached a merger agreement with Microchips Biotech of Lexington, Mass., to create a new company, Keratin Biosciences.
Xeomin, a botulinum toxin similar to Botox that is used cosmetically to smooth frown lines between the eyebrows, is becoming an ever more versatile product for Raleigh-based Merz North America. The FDA just approved it to treat chronic sialorrhea, or excessive drooling, in adults. 
A new study conducted by researchers from Duke University, MIT and Singapore’s Nanyang Technological University shows that sound waves are capable of rapidly and efficiently separating circulating tumor cells (CTCs) from blood.
Durham-based genome editing company Precision BioSciences announced that it has raised $110 million to further the development of its proprietary ARCUS genome editing platform.
Istari Oncology, a young Research Triangle Park biotechnology company started by a world-famous Duke University brain cancer team, has reported rare positive results in a Phase 1 clinical trial of its experimental treatment for glioblastoma.
Even the best scientific innovation can be flattened by public distrust. That was the major reminder from Kevin Folta, Ph.D., a professor of horticultural sciences at the University of Florida, to dozens of people gathered at the North Carolina Biotechnology Center Wednesday. 
scroll back to top of page